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Notes on the Pharmacology of M.&B. 693 and Uleron
By J. SYDNEY MCCANN, M.D.
From the Department of Pharmacology, Queen's University, Belfast
IT is intended here merely to give an outline of the results obtained in a large series
of experiments performed in the study of the absorption and excretion of M.&B. 693
and of some of the toxic effects of that drug and Uleron. Experimental detail will
not bte described.
ABSORPTION AND EXCRETIION OF M.&B. 693.
Various methods have been employed in the estimation of the sulphonamides in
the body fluids. The method used in the present investigation was that described
by Werner (1939).
M.&B. 693 is absorbed from the gastro-intestinal tract and appears in the blood-
stream and urine within half an hour after its ingestion by mouth. The maximum
concentration is reached in from two to five hours time, the maximum urinary output
being delayed for from half an hour to five hours after the blood peak has been
reached. After a single (lose of the drug, M.&B. 693 can still be detected in the
blood for forty-eight to sixty hours and in the urine for eighty-four hours, whilst,
with repeatedl (losage, it has been recovered from the blood thirty-six hours and
from the urine sixty hours after the last dose, a point of importance in view of the
toxicity of the drug. The output of the drug varies with diuresis, but large amounts
of fluids appear to wash it through the bowel too rapidly for complete absorption
from the intestine to take place, and the urinary output is thus considerably less
than on a low fluid intake: Baines and Wien (1939) have shown that normally a
small amount of the drug is excreted in the faeces, and it is likely that excretion,
when large amounts of fluid are administered, is chiefly through the bowel. It will
be mentioned later that in treating non-specific urinary infections, a fairly high
concentration of the drug in the urine is necessary; where such a condition is being
treated with M.&B. 693, therefore, fluids should not be given in excess. VVhere
toxic manifestations appear following absorption of M.&B. 693, forcing fluids will
tend to wash the drug out of the body. Increased fluid intake, however, does not
appear to accelerate absorption from the gastro-intestinal tract as has been shown
by others to occur with sulphanilamide (Marshall, 1939; Lucas, 1939).
A blood concentration of 2.5 milligrammes per cent. has been found to be a
reasonably satisfactory level in the treatment of most cases of gonococcal urethritis,
and this concentration can be maintained by a dosage of two grammes per day
following a heavier initial dose of three grammes during the first day's treatment.
The blood level varies with, though not in proportion to, the dosage, a reasonably
steady blood level being maintained by repeated doses given at four- to five-hourly
intervals during the period of administration of the drug. The concentration of the
drug falls during the night, and in urgent cases where a steady blood level is
desired, the last (lose of the drug should be given late at night and the first dose
74early the following morning, or an extra dose should be administered during the
night.
The drug appears in the blood and urine partly as a free, active compound and
partly as an acetylated, inert derivative. The amount of the free and acetylated
cdrug varies conbsiderably, not only from patient to patient, but in the same patient
from time to time. On an average, about twenty per cent. of the drug was found
to be in the inactive form in the blood and about forty per cent. in the urine, though
a much higher degree of acetylation sometimes occurs, figures rather lower than
those recorded by other workers (Stokinger, 1939; Long and Feinstone, 1939).
Clinical failures with M.&B. 693 are sometimes due to inadequate concentration
of the drug in the body fluids. This may be dlue to one of three things
(1) Poor absorption, or
(2) A high degree of acetylation, or
(3) A patient who requires a higher concentration of the drug than the average
patient.
WA7here failure to respond to chemotherapy is due to inadequate concentration of the
drug, increased dosage will usually result in a satisfactory clinical response.
The concentration of the free drug in the urine is of more importance than that
in the blood in the treatment of diseases due to non-specific organisms, a level of
at least fifteen to twenty milligrammes per cent. being necessary in these cases-
a figure in accord with the experimental findings of Melton and Beck (1939), who
demonstrated the marked bactericidal effect of a concentration of M.&B. 693 of
fifteen milligrammes per cent. in urine to which varying dilutions of B. coli had
been added. This concentration is very often not obtained when fluids are forced
(see above).
With poor excretion, accumulation of the drug in the tissues occurs and toxic
manifestations, often in proportion to the amount of the drug in the tissues, are
seen.
TOXIC MANIFEST'ATIONS.
In common with sulphanilamide, both M.&B. 693 and Uleron show a high degree
of toxicity. Many "minor" toxic reactions are common with M.&B. 693, especially
nausea, flatulence, headache, and (particularly in females) vomiting. These "minor"
reactions are much less common with Uleron. The use of both drugs, however,
is often followed by more serious toxic manifestations, which are often missed or
unrecognised. Of these, the most important are the effects of the drugs on the
blood cells of the body and on the kidneys, whilst a less urgent, though often more
alarming, toxic effect is the occurrence of skin rashes and drug fever following
ingestion, especially of M.&B. 693.
(1) EFFECT ON THE BLOOD.
Both drugs have a marked effect in reducing the numbers of both the white and
red blood cells, the effect on the red blood cells being of a more transient nature
than that on the leucocytes. The lowering of the white blood cell count is chiefly
the result of a decrease in the numbers of the neutrophils. With a dosage of
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FM.&B. 693 of three grammes for one day, followed by two grammes daily for a
further six davs, thirty-two per cent. of cases showed an absolute neutropenia on
one or more occasions, whilst a relative neutropenia occurred in no less thani eighty-
three per cent. in a large series of patients investigated. Ihis phenomenon was
seen not only (luring administration of the drug but for some considerable time
afterwards, the maximum lowering of the blood-cell count in the cases examined
(in the case of MI.&B. 693) occurring nine days after cessation of chemotherapy.
This depressive action of M.&B. 693 on the blood cells does not appear to depend
on the concentration of the free drug in the body fluids.
A number of cases of graniulocvtopenia have been recorded following the use of
M.&B. 693, and in several of these cases at least the con(lition dlid not develop
until several days after withdrawal of the (Irug (Barnett et al., 1939; Graham et al.,
1939; grarnat et al., 1939; and Briggs, 1939). In some of these cases (Briggs,
19:39) an atypical response to chemotherapy was witnessed. It would appear to be
important, therefore, to keep a close watch on the blood, especially where prolonged
chemotherapy, heavy dosage, or atypical response occur, and blood examinations
in these cases shoulcd be continuedl periodically for several days (ten to fourteen at
least) followving- the endl of chemotherapy.
Uleron has an even more marked effect in reducing the blood-cell counts than
M.&B. 693.
Cvanosis occurs occasionally with both M.&B. 693 and Uleron, though methe-
moglobin was found once only on spectroscopic examination of the blood of a patient
who had had an unusually heavy dosage of M.&B. 693 within a short period of
time. Repeated spectroscopic examination of the blood in patients on routine
dosage of M.&B. 693 and Uleron failed to reveal either met- or sulphaemoglobin.
(2) EFFECT ON THE KIDNEYS.
Another toxic manifestation of considerable importance, which has been found
to complicate therapy with these drugs, is haematuria (McCann, 1939). Micro-
scopical haematuria has been found in fifty-two per cent. of cases treated with
M.&B. 693 (of which thirteen per cent. may have had a traumatic origin) and in
twenty-nine per cent. of cases treated with Uleron. Isolated reports have appeared
from time to time describing gross hamaturia occurring with both Uleron and
M.&B. 693 (Sommer, 1938; Muller, 1938; Adalja, 1939; and others); these reports
included at least one fatal case (Tsao et al., 1939). Experimental haematuria has
also been produced (Gross and Cooper, 1939; Antopol and Robinson, 1939). The
cause of the phenomenon is still a matter of conjecture, but in the more severe
cases at least, and in experimental animals, it would appear to be due to the
deposit of needle-like crystals of the acetyl derivative of the drug in the urinary
tracts of suspectible individuals. In the series of cases analysed personally,
haematuria was found to be more common in M.&B.-693-treated patients, where
the percentage of the acetylated drug in the urine was high. X-ray and blood-urea
examinations in a number of cases where haematuria was seen, revealed no
pathology of the renal tract, but the possibility of renal calculi following chemo-
therapy with M.&B. 693 and Uleron cannot be overlooked. Time alone will either
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those now in our possession should be discarded on this account; it is important,
however, that they be used with due consideration to their toxic possibilities.
Where gross haematuria occurs, as in the case of other severe toxic manifesta-
tions, the drugs should be withheld and large amounts of fluids should be given
in order to xvash the drug out of the tissues.
(3) EFFECTS ON THE SKIN.
The skin reactions observed may follow exposure to artificial or natural sunlight
or may occur apart from such exposure. Skin rashes occurred in only four patients
treated personally with M.&B. 693, and in only one of these patients was there
any suggestion of light-sensitivity. In three cases the dosage was small, the rash
appearing on the eighth morning from beginning of chemotherapy in one case and
on the tenth morning in two cases. In the fourth case, the rash occurred on the
fourteenth day from beginning a second course of the drug. In one case, the
dermatitis was accompanied by drug fever, whilst in this case as well as in one
other, considerable gastric upset was seen when the drug was being taken. The
time factor was of interest in these cases and was similar to that found by Erskine
(1939) and Thompson (1939), the skin eruptions occurring in their cases between
the eighth and txvelfth days of administration of the dlrug. It has been mentioned
that toxic manifestationis often result f'ronm the accumulationi of the drug in the
tissues, and such would appear tio be a possible explanation of the skin rashes
occurring in at least two of the cases noted personally. Again, withdrawal of the
drug and forcing fluids are indicate(l.
No skin reactions wcre seen in the Uleron-treated cases.
Various metho(ds were tried to combat the less serious though more common
"minor" toxic reactions. Some of these are described in another article in this
Journal (The Chemotherapeutic I[retatment of Gonorrhoea).
DISCUSSION.
A study of the biochemical response and the toxic manifestationis resulting from
M.&B. 693 makes it evi(lent, therefore, that whilst a "therapeutic" concentration
of the drug in the bodx' fluids is necessary for favourable clinical results, this
concentration should be obtainie(d and maintained by minimal effective dosage of
the drug. Large closes should be usedl only when the patient is confined to bed and
if possible in hospital, where constant supervision is carried out. The occurrence
of the more serious signs of toxicitv is usually an incdication for immediate cessation
of chemotherapy, especially wlhere a study of the absorption and( excretion of the
drug reveals an accumulationi in the tissues. It would seem to be important that
repeated bloo(d and( urinary examinations be performed, especially where large
doses or prolonge(d chemotherapy is being employcd or where atypical response to
the drug is manifested, and that the bloood examiniations especially should be
continue(d for some ten to fourteen (lays after with(drawal of the drug.
Equallv careful control would appear to be indicated where Uleron is the
chemotherapeutic agent in use.
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REVIEW
A HOSPITAL PRAYER BOOK. Compiled by M. L. Jacks, D. B. Porter, and
G. R. Girdlestone. 1940. Oxford University Press. Price 8d. net.
TILE Hospital Prayer Book was first published in 1913, compiled by Rev. V'erney L. Johnstone, then
Chaplain to the Wingfield-Morris Orthopaedic Hospital. It received a warm welcome from patients
and staff alike, and had an extensive circulation. The 1940 edition is a revised version, incorporating
many excellent prayers, suitable for hospitals, wvhich have been written since 1913. It includes some
of the older prayers, including the prayer of St. Ignatius: "Teach us, good Lord, to serve Thee as
Thou deservest, to give and not to count the cost, to fight and not to ask for any reward, save that
of knowing that we do Thy will, through Jesus Christ our Lord." The spirit of the first edition
has been retained, and the book should have a wide acceptance amongst the staffs and patients of
the great hospitals of our country.
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